Ose Immunotherapeutics

Ose Immunotherapeutics est une entreprise française de biotechnologie dont le siège est à Nantes en France. Elle développe différents types d'immunothérapies.

Filings

142 filings

All Inside information96 Voting rights and capital15 Earnings release10 AGM documents8 Threshold crossing5 Share buyback4 Universal registration document3 Half-year financial report1

25/08/2025
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
Inside informationFR
20/08/2025
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
Inside informationFR
12/08/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
17/07/2025
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
Inside informationFR
16/07/2025
Half-Year Report on Liquidity Contract with Invest Securities
Share buybackFR
02/07/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
02/07/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
Inside informationFR
30/06/2025
OSE Immunotherapeutics Publishes Letter to Shareholders
Inside informationFR
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings
Inside informationFR
20/06/2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
Inside informationFR
19/06/2025
Franchissement de seuils et déclaration d'intention
Threshold crossingFrench
11/06/2025
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
Inside informationFR
09/06/2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
AGM documentsFR
05/06/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
04/06/2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Inside informationFR
04/06/2025
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
AGM documentsFR
02/06/2025
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
Inside informationFR
23/05/2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025
Inside informationFR
21/05/2025
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
Inside informationFR
05/05/2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
Inside informationFR
30/04/2025
Document d'Enregistrement Universel 2024
Universal registration documentFrenchZIP
30/04/2025
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024
Universal registration documentFrench
30/04/2025
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
Earnings releaseFR
09/04/2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
Inside informationFR
03/04/2025
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
Inside informationFR
03/04/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
26/03/2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Earnings releaseFR
11/03/2025
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
Inside informationFR
06/03/2025
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
Inside informationFR
06/03/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
20/02/2025
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
Inside informationFR
04/02/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
29/01/2025
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
Inside informationFR
28/01/2025
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
Inside informationFR
13/01/2025
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
Inside informationFR
06/01/2025
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench

About

ISIN: FR0012127173
Ticker: OSE
LEI: 969500HIUWVGY6NZSM05
Sector: Health care
Founded: 2016
Country of registration: FR
Last filing: 08/07/2026, 18:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive